Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZNGA
ZYNGA INC. CL A COMMON
ZNGA
|
+$391M |
| 2 |
TransUnion
TRU
|
+$345M |
| 3 |
CERN
Cerner Corp
CERN
|
+$309M |
| 4 |
XYZ
Block Inc
XYZ
|
+$266M |
| 5 |
ATVI
Activision Blizzard
ATVI
|
+$261M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XLNX
Xilinx Inc
XLNX
|
+$561M |
| 2 |
BBL
BHP Group Plc American Depositary Shares (Each representing two Ordinary Shares)
BBL
|
+$406M |
| 3 |
RTX Corp
RTX
|
+$227M |
| 4 |
Charter Communications
CHTR
|
+$206M |
| 5 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.5% |
| 2 | Technology | 15.84% |
| 3 | Financials | 13.74% |
| 4 | Industrials | 11.78% |
| 5 | Communication Services | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Visa
V
$693B
| $286M | 1.38% |
1,291,853
-122,751
| -9% | -$26.5M |
|
27
Equifax
EFX
$22.6B
| $283M | 1.37% |
1,192,703
+187,520
| +19% | +$44.2M |
|
28
ServiceNow
NOW
$133B
| $274M | 1.32% |
2,461,750
-54,000
| -2% | -$6.05M |
|
|
ATVI
29
DELISTED
Activision Blizzard
ATVI
| $268M | 1.3% |
+3,350,000
| New | +$261M |
|
30
Broadcom
AVGO
$1.75T
| $257M | 1.24% |
4,088,500
-721,500
| -15% | -$42.9M |
|
31
Exelixis
EXEL
$13.4B
| $238M | 1.15% |
10,520,061
+1,660,904
| +19% | +$32.4M |
|
32
AstraZeneca
AZN
$257B
| $237M | 1.15% |
1,788,092
+835,014
| +88% | +$100M |
|
33
AbbVie
ABBV
$468B
| $186M | 0.9% |
1,144,667
-463,784
| -29% | -$67.4M |
|
34
Alnylam Pharmaceuticals
ALNY
$31.6B
| $167M | 0.81% |
1,023,873
-166,155
| -14% | -$25.3M |
|
|
HZNP
35
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| – | – |
-1,396,217
| Closed | -$136M |
|
36
Full Truck Alliance
YMM
$9.1B
| $155M | 0.75% |
23,178,743
+9,171,000
| +65% | +$74.2M |
|
37
Beam Therapeutics
BEAM
$3.07B
| $149M | 0.72% |
2,594,387
+329,342
| +15% | +$21.6M |
|
38
Clarivate
CLVT
$1.33B
| $146M | 0.7% |
+8,713,428
| New | +$144M |
|
|
COHR
39
DELISTED
Coherent Inc
COHR
| $129M | 0.62% |
471,533
+41,533
| +10% | +$10.9M |
|
40
Avantor
AVTR
$9.78B
| $129M | 0.62% |
3,807,112
+164,254
| +5% | +$5.86M |
|
41
Lufax Holding
LU
$1.2B
| $123M | 0.59% |
5,508,600
+753,750
| +16% | +$16.6M |
|
42
CVS Health
CVS
$119B
| $120M | 0.58% |
1,186,283
-95,173
| -7% | -$10M |
|
43
Labcorp
LH
$27.3B
| $113M | 0.55% |
500,536
+18,443
| +4% | +$4.34M |
|
44
Enanta Pharmaceuticals
ENTA
$392M
| $110M | 0.53% |
1,550,000
-23,829
| -2% | -$1.55M |
|
45
KE Holdings
BEKE
$19.6B
| $108M | 0.52% |
8,713,500
+7,316,500
| +524% | +$130M |
|
46
TSMC
TSM
$2.17T
| $107M | 0.52% |
+1,028,125
| New | +$120M |
|
47
Iovance Biotherapeutics
IOVA
$3.76B
| $103M | 0.5% |
6,175,357
+113,384
| +2% | +$1.75M |
|
|
PLAN
48
DELISTED
Anaplan, Inc.
PLAN
| $102M | 0.49% |
+1,570,000
| New | +$76.5M |
|
|
NLSN
49
DELISTED
Nielsen Holdings plc
NLSN
| $101M | 0.49% |
+3,720,000
| New | +$73.9M |
|
|
BPMC
50
DELISTED
Blueprint Medicines
BPMC
| $86.7M | 0.42% |
1,356,987
+545,240
| +67% | +$39.1M |
|
Similar funds
Thomas Steyer's Q1 2022 Portfolio in Review
As of Q1 2022, Thomas Steyer held 357 positions worth $20.7B, up 3.5% from $20B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Thomas Steyer deployed $853M of net new capital in Q1 2022, opening 50 new positions and adding to 42 existing holdings. Its largest new stake was ZYNGA INC. CL A COMMON: 44,475,000 shares worth $411M.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was RTX Corp, an estimated $227M trimmed.
- Thomas Steyer's largest Q1 2022 buy was ZYNGA INC. CL A COMMON: 44,475,000 shares worth $411M.
- Thomas Steyer added most to TransUnion in Q1 2022, an estimated $345M increase.
- Thomas Steyer's biggest Q1 2022 reduction was RTX Corp, cutting an estimated $227M.
- Thomas Steyer fully exited Xilinx Inc in Q1 2022, selling an estimated $561M.
- Thomas Steyer's ten largest holdings make up 38% of its $20.7B portfolio in Q1 2022.
- Thomas Steyer opened 50 new positions and closed 37 in Q1 2022.
- Thomas Steyer's portfolio value rose 3.5% quarter-over-quarter to $20.7B.
Based on Farallon Capital Management's 13F filing for Q1 2022, filed 16 May 2022.